mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus

Background. Everolimus (Eve), which is a mammalian target of Rapamicin (mTOR) inhibitor, is part of the therapeutic armamentarium of neuroendocrine tumors (NETs). Currently, there are no validated biomarkers predicting Eve efficacy in NETs. In this study, we explore whether the expression of phospho...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelsomino, Fabio, Casadei-Gardini, Andrea, Caputo, Francesco, Rossi, Giulio, Bertolini, Federica, Petrachi, Tiziana, Spallanzani, Andrea, Pettorelli, Elisa, Kaleci, Shaniko, Luppi, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281483/
https://www.ncbi.nlm.nih.gov/pubmed/32397669
http://dx.doi.org/10.3390/cancers12051201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281483/
https://www.ncbi.nlm.nih.gov/pubmed/32397669
http://dx.doi.org/10.3390/cancers12051201

Ejemplares similares